These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Glomerulonephritis associated with Robertsonian translocation t(13;14). Li PK; Lai FM; Lee JC; Lai KN Nephron; 1992; 62(2):220-3. PubMed ID: 1436317 [TBL] [Abstract][Full Text] [Related]
10. Pure mesangial proliferative glomerulonephritis. A clinicomorphologic analysis and its possible role in morphologic transition of minimal change lesion. Andal A; Saxena S; Chellani HK; Sharma S Nephron; 1989; 51(3):314-9. PubMed ID: 2918942 [TBL] [Abstract][Full Text] [Related]
11. [Influence of immunoglobulins on clinical laboratory picture and morphological changes in patients with mesangial-proliferative glomerulonephritis: age aspects]. Sovetkina NV; Riabova TS; Ar'ev AL; Ovsiannikova NA Adv Gerontol; 2012; 25(1):63-7. PubMed ID: 22708446 [TBL] [Abstract][Full Text] [Related]
12. Naïve subset develops the most important alloreactive response among human CD4+ T lymphocytes in human leukocyte antigen-identical related setting. Chérel M; Choufi B; Trauet J; Cracco P; Dessaint JP; Yakoub-Agha I; Labalette M Eur J Haematol; 2014 Jun; 92(6):491-6. PubMed ID: 24520815 [TBL] [Abstract][Full Text] [Related]
13. Contrasting effects of steroids and mizoribine on macrophage activation and glomerular lesions in rat thy-1 mesangial proliferative glomerulonephritis. Ikezumi Y; Suzuki T; Karasawa T; Hasegawa H; Kawachi H; Nikolic-Paterson DJ; Uchiyama M Am J Nephrol; 2010; 31(3):273-82. PubMed ID: 20110667 [TBL] [Abstract][Full Text] [Related]
14. Pathological regression by angiotensin II type 1 receptor blockade in patients with mesangial proliferative glomerulonephritis. Ohtake T; Oka M; Maesato K; Mano T; Ikee R; Moriya H; Kobayashi S Hypertens Res; 2008 Mar; 31(3):387-94. PubMed ID: 18497456 [TBL] [Abstract][Full Text] [Related]
15. Proliferative glomerulonephritis with monoclonal immunoglobulin A light-chain deposits in the renal allograft. Setoguchi K; Kawashima Y; Tokumoto T; Toma H; Mizoguchi S; Horita S; Yamaguchi Y; Tanabe K Nephrology (Carlton); 2014 Jun; 19 Suppl 3():49-51. PubMed ID: 24842824 [TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic features, outcome, and therapeutic interventions in four children with isolated C3 mesangial proliferative glomerulonephritis. Yagi K; Yanagida H; Sugimoto K; Kuwajima H; Tabata N; Morita K; Okada M; Takemura T Pediatr Nephrol; 2005 Sep; 20(9):1273-8. PubMed ID: 15947989 [TBL] [Abstract][Full Text] [Related]
17. Membranoproliferative glomerulonephritis, p-antineutrophil cytoplasmic antibodies, and rheumatoid arthritis. Report of a case. Constantin A; Laroche M; Moulinier L; Bon E; Mazières B; Cantagrel A Rev Rhum Engl Ed; 1996 Feb; 63(2):141-4. PubMed ID: 8689286 [TBL] [Abstract][Full Text] [Related]
18. An anti-CD5 monoclonal antibody ameliorates proteinuria and glomerular lesions in rat mesangioproliferative glomerulonephritis. Ikezumi Y; Kawachi H; Toyabe S; Uchiyama M; Shimizu F Kidney Int; 2000 Jul; 58(1):100-14. PubMed ID: 10886554 [TBL] [Abstract][Full Text] [Related]
19. PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis. Gilbert RE; Kelly DJ; McKay T; Chadban S; Hill PA; Cooper ME; Atkins RC; Nikolic-Paterson DJ Kidney Int; 2001 Apr; 59(4):1324-32. PubMed ID: 11260393 [TBL] [Abstract][Full Text] [Related]
20. [Age-related features of the mesangial proliferative glomerulonephritis]. Riabov SI; Ar'ev AL; Riabova TS; Rakitianskaia IA Adv Gerontol; 2010; 23(2):269-73. PubMed ID: 21033382 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]